Selected research
Industry Research
Transdermal Scopolamine Industry Research Report 2026
Market perspective
The global Transdermal Scopolamine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Transdermal Scopolamine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Transdermal Scopolamine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Transdermal Scopolamine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Transdermal Scopolamine include Novartis AG, Pfizer, GlaxoSmithKline plc, Baxter International Inc., Perrigo Company plc., Nichi-Iko, Myungmoon Pharma Co. LTD. and Caleb Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Transdermal Scopolamine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Transdermal Scopolamine Market by Company
Novartis AG
Pfizer
GlaxoSmithKline plc
Baxter International Inc.
Perrigo Company plc.
Nichi-Iko
Myungmoon Pharma Co. LTD.
Caleb Pharmaceuticals, Inc.
Transdermal Scopolamine Segment by Type
Injections Type
Syrups Type
Tablet Type
Gel Type
Patch Type
Transdermal Scopolamine Segment by Application
Cough
Asthma
Parkinson's Disease
Narcotic Analgesia
Motion Sickness
Others
Transdermal Scopolamine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Scopolamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Scopolamine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Scopolamine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Transdermal Scopolamine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Transdermal Scopolamine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Transdermal Scopolamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injections Type
- Syrups Type
- Tablet Type
- Gel Type
- Patch Type
Applications
- Cough
- Asthma
- Parkinson's Disease
- Narcotic Analgesia
- Motion Sickness
- Others
Companies covered
- Novartis AG
- Pfizer
- GlaxoSmithKline plc
- Baxter International Inc.
- Perrigo Company plc.
- Nichi-Iko
- Myungmoon Pharma Co. LTD.
- Caleb Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Transdermal Scopolamine Market Size (2021-2032)
- 2.2.2 Global Transdermal Scopolamine Sales (2021-2032)
- 2.2.3 Global Transdermal Scopolamine Market Average Price (2021-2032)
- 2.3 Transdermal Scopolamine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injections Type
- 2.3.3 Syrups Type
- 2.3.4 Tablet Type
- 2.3.5 Gel Type
- 2.3.6 Patch Type
- 2.4 Transdermal Scopolamine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cough
- 2.4.3 Asthma
- 2.4.4 Parkinson's Disease
- 2.4.5 Narcotic Analgesia
- 2.4.6 Motion Sickness
- 2.4.7 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Transdermal Scopolamine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Transdermal Scopolamine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Transdermal Scopolamine Revenue of Manufacturers (2021-2026)
- 3.4 Global Transdermal Scopolamine Average Price by Manufacturers (2021-2026)
- 3.5 Global Transdermal Scopolamine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Transdermal Scopolamine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Transdermal Scopolamine, Product Type & Application
- 3.8 Global Manufacturers of Transdermal Scopolamine, Established Date
- 3.9 Global Transdermal Scopolamine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Transdermal Scopolamine Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Transdermal Scopolamine Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 GlaxoSmithKline plc
- 4.3.1 GlaxoSmithKline plc Company Information
- 4.3.2 GlaxoSmithKline plc Business Overview
- 4.3.3 GlaxoSmithKline plc Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline plc Transdermal Scopolamine Product Portfolio
- 4.3.5 GlaxoSmithKline plc Recent Developments
- 4.4 Baxter International Inc.
- 4.4.1 Baxter International Inc. Company Information
- 4.4.2 Baxter International Inc. Business Overview
- 4.4.3 Baxter International Inc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter International Inc. Transdermal Scopolamine Product Portfolio
- 4.4.5 Baxter International Inc. Recent Developments
- 4.5 Perrigo Company plc.
- 4.5.1 Perrigo Company plc. Company Information
- 4.5.2 Perrigo Company plc. Business Overview
- 4.5.3 Perrigo Company plc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Perrigo Company plc. Transdermal Scopolamine Product Portfolio
- 4.5.5 Perrigo Company plc. Recent Developments
- 4.6 Nichi-Iko
- 4.6.1 Nichi-Iko Company Information
- 4.6.2 Nichi-Iko Business Overview
- 4.6.3 Nichi-Iko Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Nichi-Iko Transdermal Scopolamine Product Portfolio
- 4.6.5 Nichi-Iko Recent Developments
- 4.7 Myungmoon Pharma Co. LTD.
- 4.7.1 Myungmoon Pharma Co. LTD. Company Information
- 4.7.2 Myungmoon Pharma Co. LTD. Business Overview
- 4.7.3 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Product Portfolio
- 4.7.5 Myungmoon Pharma Co. LTD. Recent Developments
- 4.8 Caleb Pharmaceuticals, Inc.
- 4.8.1 Caleb Pharmaceuticals, Inc. Company Information
- 4.8.2 Caleb Pharmaceuticals, Inc. Business Overview
- 4.8.3 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Product Portfolio
- 4.8.5 Caleb Pharmaceuticals, Inc. Recent Developments
5 Global Transdermal Scopolamine Market Scenario by Region
- 5.1 Global Transdermal Scopolamine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Transdermal Scopolamine Sales by Region: 2021-2032
- 5.2.1 Global Transdermal Scopolamine Sales by Region: 2021-2026
- 5.2.2 Global Transdermal Scopolamine Sales by Region: 2027-2032
- 5.3 Global Transdermal Scopolamine Revenue by Region: 2021-2032
- 5.3.1 Global Transdermal Scopolamine Revenue by Region: 2021-2026
- 5.3.2 Global Transdermal Scopolamine Revenue by Region: 2027-2032
- 5.4 North America Transdermal Scopolamine Market Facts & Figures by Country
- 5.4.1 North America Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Transdermal Scopolamine Sales by Country (2021-2032)
- 5.4.3 North America Transdermal Scopolamine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Transdermal Scopolamine Market Facts & Figures by Country
- 5.5.1 Europe Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Transdermal Scopolamine Sales by Country (2021-2032)
- 5.5.3 Europe Transdermal Scopolamine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Transdermal Scopolamine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Transdermal Scopolamine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Transdermal Scopolamine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Transdermal Scopolamine Market Facts & Figures by Country
- 5.7.1 South America Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Transdermal Scopolamine Sales by Country (2021-2032)
- 5.7.3 South America Transdermal Scopolamine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Transdermal Scopolamine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Transdermal Scopolamine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Transdermal Scopolamine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Transdermal Scopolamine Sales by Type (2021-2032)
- 6.1.1 Global Transdermal Scopolamine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Transdermal Scopolamine Sales Market Share by Type (2021-2032)
- 6.2 Global Transdermal Scopolamine Revenue by Type (2021-2032)
- 6.2.1 Global Transdermal Scopolamine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Transdermal Scopolamine Revenue Market Share by Type (2021-2032)
- 6.3 Global Transdermal Scopolamine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Transdermal Scopolamine Sales by Application (2021-2032)
- 7.1.1 Global Transdermal Scopolamine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Transdermal Scopolamine Sales Market Share by Application (2021-2032)
- 7.2 Global Transdermal Scopolamine Revenue by Application (2021-2032)
- 7.2.1 Global Transdermal Scopolamine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Transdermal Scopolamine Revenue Market Share by Application (2021-2032)
- 7.3 Global Transdermal Scopolamine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Transdermal Scopolamine Value Chain Analysis
- 8.1.1 Transdermal Scopolamine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Transdermal Scopolamine Production Mode & Process
- 8.2 Transdermal Scopolamine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Transdermal Scopolamine Distributors
- 8.2.3 Transdermal Scopolamine Customers
9 Global Transdermal Scopolamine Analyzing Market Dynamics
- 9.1 Transdermal Scopolamine Industry Trends
- 9.2 Transdermal Scopolamine Industry Drivers
- 9.3 Transdermal Scopolamine Industry Opportunities and Challenges
- 9.4 Transdermal Scopolamine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst